Zydus partners Medicure to launch its NDA product, ZYPITAMAG

Zydus Cadila which is a leading innovation-driven, global healthcare provider asserted that it has entered into a definitive agreement with Medicure International which is subsidiary of Medicure to commercialize its 505(b)(2) New Drug Application (NDA) product, pitavastatin magnesium (ZYPITAMAG) in the United States.

The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the U.S.

Dr. Sharvil Patel, Managing Director, Zydus Cadila said, “The launch of this proprietary drug is in continuation of our commitment to exploring new pathways in pharmaceutical technology with a thrust on enhancing patient care and well-being. In this endeavour, we are happy to partner with Medicure in reaching out to the patient community and helping them access this NDA for desired health outcomes.”

The strengths approved in the range of 1 mg, 2 mg and 4 mg , ZYPITAMAG is an HMG-CoA reductase inhibitor indicated for patients with primary hyperhyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).